CClinicalTrials.gg
Sign In
RecruitingNCT04274868HEPATOBIOUpdated Feb 18, 2020

Pediatric Hepatic Tumors

An observational study in Liver Tumor, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 1 site in France. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2020-02-18.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Sep 2015; still recruiting 11 years later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
600
Ages
Up to 18 Years
Sex
All
01

Study summary

Centralized biological collection of multicentric origin, retrospective and prospective of biological samples (tissues and fluids) taken within the framework of the diagnostic and therapeutic management of children and adolescents with liver tumor, and supported in the centers of French Society for Childhood Cancers (SFCE) with associated clinical database.

02

Conditions studied

  • Liver Tumor

Browse trials for

03

In context

Liver Neoplasms

1,391 studies on the registry are indexed under Liver Neoplasms; 345 are open to participants now.

This study's planned enrollment of 600 is above the median of 200 across 350 observational studies indexed under Liver Neoplasms.

Browse Liver Neoplasms studies →

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 242 studies on the registry; 65 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients treated after 01/01/1990 for a primary liver tumor before the age of 18.

Inclusion criteria

    • For inclusion in the clinical database:

      • Children and adolescents (≤18 years at diagnosis) suffering from a primary liver tumor diagnosed after 01/01/1990 and treated in France
      • Informed consent to the computerization of data signed by the patient or by parents or legal representatives if he is a minor.

    • For inclusion in the biological collection (CRB Paris Sud):

      • Additional criteria:
      • Availability of biological samples (tumor tissue, healthy tissue, plasma and / or serum).
      • Informed consent to the use of biological remains signed by the patient or by parents or legal representatives if he is a minor.

    • For the inclusion of deceased patients:

      • Obtaining consent or failing this, seeking non-opposition to the computerization of data (for inclusion in the database) and the use of biological remains (for inclusion in the biological collection) of the patient or both parents or the legal guardian if he is a minor.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
600 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Children and adolescents with liver tumor

    Patients treated after 01/01/1990 for a primary liver tumor before the age of 18.

06

What researchers measure

Primary outcomes

  1. Establish a national bank of rare biological material

    Time frame: Up to 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04274868
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Responsible party
Sponsor
First posted
Feb 18, 2020
Start date
Sep 10, 2015
Primary completion
Sep 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Feb 18, 2020

Study contacts

Brenda Mallon
Contact
branda.mallon@gustaveroussy.fr
0142114211 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Liver Neoplasms→

Other studies from this sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Start the discussion